McCune C S, O'Donnell R W, Marquis D M, Sahasrabudhe D M
University of Rochester Cancer Center, University of Rochester School of Medicine and Dentistry, New York 14642.
Cancer Immunol Immunother. 1990;32(1):62-6. doi: 10.1007/BF01741726.
Eighteen patients with metastatic renal cell carcinoma, who were treated by vaccines for active specific immunotherapy, also completed skin testing with autologous tumor cells, both prior to and following vaccine treatment. All patients have now been followed for more than 5 years. Ten patients who remained skin-test-negative following treatment had no clinical responses, and all had expired by 22 months. Eight patients became skin-test-positive; three of these had clinical regressions and three remain alive after more than 69 months. The survival times of the skin-test-positive group were significantly superior to those of the skin-test-negative group. The results suggest that skin testing with autologous tumor cells may accurately identify those patients who have acquired antigen-specific cell-mediated antitumor immunity.
18例接受疫苗主动特异性免疫治疗的转移性肾细胞癌患者，在疫苗治疗前后均用自体肿瘤细胞进行了皮肤试验。所有患者目前均已随访超过5年。治疗后皮肤试验仍为阴性的10例患者无临床反应，均在22个月内死亡。8例患者皮肤试验转为阳性；其中3例出现临床缓解，3例在超过69个月后仍存活。皮肤试验阳性组的生存时间显著优于皮肤试验阴性组。结果表明，用自体肿瘤细胞进行皮肤试验可能准确识别那些获得了抗原特异性细胞介导抗肿瘤免疫的患者。
